These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38741224)

  • 1. High-dose naloxone formulations are not as essential as we thought.
    Lemen PM; Garrett DP; Thompson E; Aho M; Vasquez C; Park JN
    Harm Reduct J; 2024 May; 21(1):93. PubMed ID: 38741224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Dose Naloxone Formulations Are Not as Essential as We Thought.
    Lemen PM; Garrett DP; Thompson E; Aho M; Vasquez C; Park JN
    medRxiv; 2023 Aug; ():. PubMed ID: 37645849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.
    Strickland JC; Marks KR; Smith KE; Ellis JD; Hobelmann JG; Huhn AS
    Int J Drug Policy; 2022 Aug; 106():103751. PubMed ID: 35636070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
    Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
    Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021.
    Rock P; Slavova S; Westgate PM; Nakamura A; Walsh SL
    Drug Alcohol Depend; 2024 Feb; 255():111062. PubMed ID: 38157702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings: A Systematic Review.
    Chou R; Korthuis PT; McCarty D; Coffin PO; Griffin JC; Davis-O'Reilly C; Grusing S; Daya M
    Ann Intern Med; 2017 Dec; 167(12):867-875. PubMed ID: 29181532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-Overdose Extended-Release Buprenorphine Initiation Facilitated by a Partnership Between Emergency Medical Services and an Outpatient Substance Use Disorder Observation Unit.
    Taylor JL; Gott J; Weisenthal K; Colicchio P; Dyer S; Komaromy MS
    Subst Use Addctn J; 2024 Oct; 45(4):771-776. PubMed ID: 38736211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher naloxone dosing may be required for opioid overdose.
    Bardsley R
    Am J Health Syst Pharm; 2019 Oct; 76(22):1835-1837. PubMed ID: 31665765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time.
    Stolbach AI; Mazer-Amirshahi ME; Nelson LS; Cole JB
    Clin Toxicol (Phila); 2023 Nov; 61(11):952-955. PubMed ID: 38039052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults.
    Dale O
    Expert Opin Drug Metab Toxicol; 2022 Mar; 18(3):203-217. PubMed ID: 35500297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data.
    Mahonski SG; Leonard JB; Gatz JD; Seung H; Haas EE; Kim HK
    Clin Toxicol (Phila); 2020 Feb; 58(2):117-123. PubMed ID: 31092050
    [No Abstract]   [Full Text] [Related]  

  • 14. Intranasal Naloxone for Opioid Overdose.
    Taylor JL; Lasser KE
    JAMA; 2024 Jan; 331(3):250-251. PubMed ID: 38127361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.
    Carpenter J; Murray BP; Atti S; Moran TP; Yancey A; Morgan B
    J Med Toxicol; 2020 Jan; 16(1):41-48. PubMed ID: 31471760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Fentanyl Test Strip Use, Perceived Overdose Risk, and Naloxone Possession among People Who Use Drugs.
    Tilhou AS; Zaborek J; Baltes A; Salisbury-Afshar E; Malicki J; Brown R
    Subst Use Misuse; 2024; 59(2):254-257. PubMed ID: 37807227
    [No Abstract]   [Full Text] [Related]  

  • 17. Stronger, longer, better opioid antagonists? Nalmefene is NOT a naloxone replacement.
    Infante AF; Elmes AT; Gimbar RP; Messmer SE; Neeb C; Jarrett JB
    Int J Drug Policy; 2024 Feb; 124():104323. PubMed ID: 38232438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level.
    Moss RB; Pryor MM; Baillie R; Kudrycki K; Friedrich C; Reed M; Carlo DJ
    PLoS One; 2020; 15(6):e0234683. PubMed ID: 32544184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal.
    Strang J; McDonald R; Alqurshi A; Royall P; Taylor D; Forbes B
    Drug Alcohol Depend; 2016 Jun; 163():16-23. PubMed ID: 26996745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.
    Saari TI; Strang J; Dale O
    Clin Pharmacokinet; 2024 Apr; 63(4):397-422. PubMed ID: 38485851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.